LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Sold by Kelleher Financial Advisors

Kelleher Financial Advisors cut its holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ) by 18.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 17,023 shares of the company’s stock after selling 3,750 shares during the quarter. Kelleher Financial Advisors’ holdings in LENZ Therapeutics were worth $491,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Harbor Capital Advisors Inc. acquired a new position in shares of LENZ Therapeutics during the fourth quarter worth about $1,270,000. Parkman Healthcare Partners LLC purchased a new stake in LENZ Therapeutics during the third quarter worth about $3,308,000. The Manufacturers Life Insurance Company purchased a new stake in LENZ Therapeutics during the third quarter worth about $743,000. Charles Schwab Investment Management Inc. boosted its holdings in LENZ Therapeutics by 197.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 123,371 shares of the company’s stock worth $2,929,000 after buying an additional 81,901 shares in the last quarter. Finally, State Street Corp boosted its holdings in LENZ Therapeutics by 18.7% during the third quarter. State Street Corp now owns 289,154 shares of the company’s stock worth $6,865,000 after buying an additional 45,600 shares in the last quarter. 54.32% of the stock is currently owned by institutional investors and hedge funds.

LENZ Therapeutics Stock Up 2.7 %

Shares of NASDAQ LENZ opened at $24.46 on Thursday. The firm’s 50-day moving average is $30.97 and its two-hundred day moving average is $26.54. LENZ Therapeutics, Inc. has a 12-month low of $14.42 and a 12-month high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.09. During the same quarter in the previous year, the company posted ($1.33) EPS. As a group, equities analysts predict that LENZ Therapeutics, Inc. will post -2.18 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

LENZ has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and set a $38.00 price objective on shares of LENZ Therapeutics in a report on Thursday, November 7th. Raymond James initiated coverage on shares of LENZ Therapeutics in a report on Friday, September 27th. They issued an “outperform” rating and a $37.00 price target on the stock. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, LENZ Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $35.40.

LENZ Therapeutics Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.